Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma

Active:	Yes
Cancer Type:	Cervical Cancer Unknown Primary	NCT ID:	NCT03108495
Trial Phases:	Phase II	Protocol IDs:	C-145-04 (primary) NCI-2017-01051 2016-003447-11
Eligibility:	18 Years and older, Female	Study Type:	Treatment
Study Sponsor:	Iovance Biotherapeutics, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT03108495

Summary

Prospective, multicenter, single-arm, open label, interventional study evaluating adoptive
cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (LN-145)
followed by IL-2 after a non-myeloablative (NMA) lymphodepletion preparative regimen for the
treatment of patients with recurrent, metastatic, or persistent cervical carcinoma

Objectives

LN-145 is an adoptive cell transfer therapy that utilizes an autologous TIL manufacturing
process, as originally developed by the NCI, for the treatment of patients with recurrent,
metastatic, or persistent cervical carcinoma. The cell transfer therapy used in this study
involves patients receiving a NMA lymphocyte depleting preparative regimen, followed by
infusion of autologous TIL followed by the administration of a regimen of IL-2.

Treatment Sites in Georgia

Georgia Cancer Center at Augusta University
1411 Laney Walker Boulevard
Augusta, GA 30912
www.augusta.edu/cancer/

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.